The Role of Melatonin in the Immuno-Neuro-Psychology of Mental Disorders
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Melatonin (N-acetyl-5-methoxytryptamine) is a molecule known to be produced in multiple cells and organs. It acts at the level of the biological clock, the suprachiasmatic nuclei, to modulate their activity, thereby influencing circadian rhythms, and also sleep processes. The clinical application of melatonin in the treatment of human mental disorders is still in its infancy. Until now, melatonin only has been used in psychiatry because of its hypnotic, resynchronizing and antioxidant actions. In this review, we hypothesized that melatonin might play an important role as an adjuvant therapy, in mental disturbances, due to other properties including its anti-inflammatory, antinociceptive, anxiolytic, drug detoxification properties, protective actions against osteoporosis, etc. Complex interactions occur between the brain and the immune system and currently is accepted that psychological and psychiatric illness can compromise immune and hormonal functions. Altered psychological states often influence the susceptibility of an individual to illness or modify the course of the illness and its prognosis. The present review discusses on the advantages of the co-treatment with melatonin and recent patents in three major psychiatric disorders: depression, bipolar syndrome and schizophrenia. The findings suggest new vistas in both the pathophysiology and the pharmacology of mental disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia
Walsh, T., McClellan, J. M., McCarthy, S. E., Addington, A. M., Pierce, S. B., Cooper, G. M., Nord, A. S., Kusenda, M., Malhotra, D., Bhandari, A., et al. (2008) · Science · doi:10.1126/science.1155174 · Cited by 1,800
Tan, D., Manchester, L. C., Terron, M. P., Flores, L. J., & Reiter, R. J. (2007) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2006.00407.x · Cited by 1,601
Self-citationGeddes, J. R., Burgess, S., Hawton, K., Jamison, K., & Goodwin, G. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.217 · Cited by 661
Srinivasan, V., Smits, M., Spence, W., Lowe, A. D., Kayumov, L., Pandi-Perumal, S. R., Parry, B., & Cardinali, D. P. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970600571822 · Cited by 292
Association of Low Bone Mineral Density With Selective Serotonin Reuptake Inhibitor Use by Older Men
Haney, E. M. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.12.1246 · Cited by 286
Should Depressive Syndromes Be Reclassified as “Metabolic Syndrome Type II”?
McIntyre, R. S., Soczynska, J. K., Konarski, J. Z., Woldeyohannes, H. O., Law, C. W. Y., Miranda, A., Fulgosi, D., & Kennedy, S. H. (2007) · Annals of Clinical Psychiatry · doi:10.1080/10401230701653377 · Cited by 277
Carrillo‐Vico, A., Lardone, P. J., Naji, L., Fernández‐Santos, J. M., Martín‐Lacave, I., Guerrero, J. M., & Calvo, J. R. (2005) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2005.00265.x · Cited by 204
HPA and Immune Axes in Stress: Involvement of the Serotonergic System
Leonard, B. E. (2006) · Neuroimmunomodulation · doi:10.1159/000104854 · Cited by 169
Melatonin in Schizophrenic Outpatients With Insomnia: A Double-Blind, Placebo-Controlled Study
Kumar, P. N. S., Andrade, C., Bhakta, S. G., & Singh, N. M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0208 · Cited by 102
T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients.
Kim, Y.-K., Myint, A.-M., Lee, B.-H., Han, C.-S., Lee, S.-W., Leonard, B. E., & Steinbusch, H. W. M. (2004) · Psychiatry Research · doi:10.1016/j.psychres.2004.08.005 · Cited by 100
Inflammation and depression: Is there a causal connection with dementia?
E.Leonard, B., & Myint, A. (2006) · Neurotoxicity Research · doi:10.1007/bf03033243 · Cited by 76
Cognitive impairment in later life in patients with early‐onset bipolar disorder
Tsai, S., Lee, H., Chen, C., & Huang, Y. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00498.x · Cited by 70
Neutrophilia and lymphopenia in major mood disorders
Darko, D. F., Rose, J., Christian Gillin, J., Golshan, S., & Baird, S. M. (1988) · Psychiatry Research · doi:10.1016/0165-1781(88)90095-9 · Cited by 70
Cited by
Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin
Reiter, R. J., Paredes, S. D., Manchester, L. C., & Tan, D.-X. (2009) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230903044914 · Cited by 478
Self-citationLoftis, J. M., Huckans, M., & Morasco, B. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.015 · Cited by 252
Neurotoxins: Free radical mechanisms and melatonin protection
J. Reiter, R., C. Manchester, L., & Tan, D.-X. (2010) · Current Neuropharmacology · doi:10.2174/157015910792246236 · Cited by 179
Anderson, G., & Maes, M. (2012) · Metabolic Brain Disease · doi:10.1007/s11011-012-9307-9 · Cited by 105
“Melatonin is not only a hypnotic and circadian rhythm resynchronizing compound, it is also a strong antioxidant and antiinflammatory agent (Maldonado et al. 2009a, b).”
Sleep and inflammatory markers in different psychiatric disorders
Krysta, K., Krzystanek, M., Bratek, A., & Krupka-Matuszczyk, I. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-015-1492-3 · Cited by 53
“Nevertheless, it is noteworthy that melatonin is additionally involved in immunomodulation (Maldonado et al. 2009), attenuates pro-inflammatory”
Background
Metadata
- Authors
- Maldonado, M., Perez-San-Gregorio, M., & Reiter, R.
- Venue
- Recent Patents on CNS Drug Discovery
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-01-01
- Volume
- 4
- Issue
- 1
- Pages
- 61-69
- ISSN
- 1574-8898 (ISSN-L)
- OpenAlex
- W2135564221
- Cited by
- 38
- References
- 13
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.